ARVINAS, INC. Proceeds from Long-Term Debt Issued
ARVINAS, INC. (ARVN) reported Proceeds from Long-Term Debt Issued of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2021-03-01
- ARVINAS, INC. proceeds from issuance of long-term debt for the quarter ending 2019-12-31 was $0.00.
- ARVINAS, INC. proceeds from issuance of long-term debt for the quarter ending 2018-12-31 was $0.00.
- ARVINAS, INC. proceeds from issuance of long-term debt for the quarter ending 2017-12-31 was $0.00.
- ARVINAS, INC. proceeds from issuance of long-term debt for fiscal 2020 was $0.00.
- ARVINAS, INC. proceeds from issuance of long-term debt for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- ARVINAS, INC. proceeds from issuance of long-term debt for fiscal 2018 was $2.00M.
- ARVINAS, INC. proceeds from issuance of long-term debt for fiscal 2017 was $0.00.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-01 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 | |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-04 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $2.00M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $2.00M 10-Q · filed 2019-11-04 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $0.00 10-K · filed 2019-03-26 | |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |